TELO: Telomir Pharma Kompaniya qiymatining sof foydaga nisbati

Telomir Pharmaceuticals Inc (TELO) korporativ emblemasi va logotipi

Telomir Pharmaceuticals (TELO) hozirda joriy daromad olmagan holda, mavjud naqd pullarini operatsion faoliyatga tajovuzkor tarzda sarflamoqda. Qarishga qarshi tadqiqotlar bilan bog'liq yuqori ilmiy risklar nol daromadlilik xavfini tug'diradi. -0.70 metrikasi aks etgan ushbu aksiya narxi grafigi aktivning narx dinamikasini vizuallashtiradi. Biznes telomerlar regulyatsiyasini o'rganishga tayanadi va investitsiyalarini xedj qilish uchun o'z portfelini veterinariya loyihalari hamda fibroz davolash vositalari bilan kengtirmoqda.

TELO Telomir Pharmaceuticals Corp: Narx-foyda koeffitsiyenti 21.02.2024 - 16.11.2026 oraligʻida

Telomir Pharmaceuticals Inc (TELO) boʻyicha keng qamrovli koʻrsatkichlar kesimi va tahlil

- narx va narxlar bo'yicha konsensus prognoz:
Kompaniyaning har tomonlama tahlili:Telomir Pharma - TELO
Telomir Pharmaceuticals, Inc. yetakchi tovari

Emitentning investitsiya auditini o'tkazish P/E tahlilini talab qiladi, u bozor kapitalizatsiyasining sof foydaga nisbati sifatida hisoblanadi va joriy daromadlar asosida investitsiyalarning qoplash muddatini belgilaydi. Qarishga qarshi kurashda R&D to'siqlarini yaratayotgan Telomir Pharmaceuticals (TELO) uchun P/E biznes baholash innovatsion molekula qiymatini haqiqiy daromadlilik bilan bog'lash imkonini beradi va texnologik kutuvlar uchun haddan tashqari ko'p to'lov qilishning oldini oladi.

Raqobatdosh kompaniyalar

HLN: Kompaniya qiymatining sof foydaga nisbati|Narx-foyda koeffitsiyenti KVUE (Kenvue Corp)|VRNA (Verona Pharma Inc.) - Kompaniya qiymatining sof foydaga nisbati|Narxning foydaga nisbati Jyong Biotech Limited MENS|Ligand (LGND) - Kapitalizatsiyaning foydaga nisbati|AMRX: Narx-foyda koeffitsiyenti|Perrigo - Bozor narxining sof foydaga nisbati|ALVO: P/E multiplikatori|Liquidia Technologies - Kompaniya qiymatining sof foydaga nisbati|GLPG (Galapagos N.V.) - P/E multiplikatori|Kapitalizatsiyaning foydaga nisbati anipharmaceuticals.com ANIP|Narxning foydaga nisbati MannKind (MNKD)|AMPH (Amphastar Pharmaceuticals, Inc.) - Kompaniya qiymatining sof foydaga nisbati|Narxning foydaga nisbati Pacira BioSciences, Inc. PCRX|P/E multiplikatori ARS Corp SPRY|Theravance Biopharma - P/E multiplikatori|Kapitalizatsiyaning sof foydaga nisbati koeffitsiyenti Aquestive Therapeutics, Inc. (AQST)|scPharmaceuticals (SCPH) - Narxning foydaga nisbati|Narx-foyda koeffitsiyenti Tectonic Therapeutic, Inc.|TNXP (Tonix Pharmaceuticals Holding) - P/E multiplikatori|Narx-foyda multiplikatori SXTC (China SXT Pharmaceuticals)|P/E multiplikatori EPRX|P/E multiplikatori bioharvest.com (BHST)|Narxning foydaga nisbati Invizyne Technologies EXOZ|ORMP: Narx-foyda multiplikatori|ENTX: Narx-foyda koeffitsiyenti|HYFT: Narxning foydaga nisbati|ABVC BioPharma Inc. (ABVC) - Narxning foydaga nisbati|cumberlandpharma.com (CPIX) - P/E multiplikatori|QNTM (Quantum BioPharma) - P/E multiplikatori|FGEN: Kompaniya qiymatining sof foydaga nisbati|P/E multiplikatori RANI|SNYR (Synergy CHC) - Kompaniya qiymatining sof foydaga nisbati|Narxning foydaga nisbati Rallybio RLYB|Lexaria Bioscience (LEXX) - Kapitalizatsiyaning foydaga nisbati|PULM - Narxning foydaga nisbati|Biznesning o‘zini qoplash muddati Pheton Holdings PTHL|APM (Aptorum) - Narx-foyda koeffitsiyenti|Lyra Therapeutics, Inc. (LYRA) - P/E multiplikatori|IBO (impactbiomedinc.com) - P/E multiplikatori|TNFA (TNF Pharmaceuticals) - Bozor narxining sof foydaga nisbati|Narxning foydaga nisbati cbdmd.com (YCBD)|Biznesning o‘zini qoplash muddati PainReform Ltd|P/E multiplikatori CYTO (Altamira Therapeutics Ltd.)|Lipella Pharmaceuticals (LIPO) - Kapitalizatsiyaning foydaga nisbati|OPTN - Narxning foydaga nisbati|Pieris Pharmaceuticals - Bozor narxining sof foydaga nisbati|PROC (Procaps Group) - Narx-foyda koeffitsiyenti|PTPI - Biznesning o‘zini qoplash muddati|Narxning foydaga nisbati Qilian International Holding Group Limited|SLRN: Kompaniya qiymatining sof foydaga nisbati|Narx-foyda koeffitsiyenti TFFP (TFF Pharma)